Download Free Medical Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIV-infected Asian children stable on first-line cART PowerPoint Presentation

Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIV-infected Asian children stable on first-line cART PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIV-infected Asian children stable on first-line cART

Tags : Pediatrics, Child Health, pediatric practice, pediatrician, health providers, HIV-infected infants, plasma viral

Published on : Jul 16, 2020 | Views : 2265 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIV- infected Asian children stable on first-line NNRTI-based cART T Sudjaritruk, DC Boettiger, NV Lam, KAM Razali, DK Wati, T Bunupuradah, R Hansudewechakul, PS Ly, P Lumbiganon, RA Nallusamy, MS Fong, K Chokephaibulkit, NKN Yusoff , TH Khanh, DC Viet, AH Sohn, V Sirisanthana, for the TREAT Asia Pediatric HIV Observational Database
Slide 2-

Introduction Plasma viral load (pVL) is a reliable indicator of initial and sustained response to cART. It can be measured in HIV-infected patients at entry into care, at initiation of therapy, and on a regular basis thereafter. – The availability and cost are obstacles to using pVL in monitoring HIV treatment outcomes in resource-constrained settings Recommendations on the optimal frequency of pVL monitoring in HIV-infected children stable on cART are inconsistent.
Slide 3-

Recommendations on the frequency of pVL testing 1WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – 2nd ed. 2016. 2Panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Department of Health and Human Services. 3A Bamford, A Turkova, H Lyall, et al. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. 4Thailand national guidelines on HIV/AIDS treatment and prevention 2014.
Slide 4-

Objectives To determine the impact of annual vs. semi- annual pVL testing on treatment outcomes among perinatally HIV-infected children stable on first-line NNRTI-based cART. To evaluate factors associated with treatment failure in this population.
Slide 5-

Methods Study design: Retrospective cohort study Study cohort: The TREAT Asia pediatric HIV Observational Database (TApHOD) Sites: Cambodia (n=1), India (n=1), Indonesia (n=2), Malaysia (n=4), Thailand (n=5), Vietnam (n=3) Data: 5,783 children receiving care from all 16 sites Study population: HIV-infected children enrolled in TApHOD before March 30, 2015
Slide 6-

Methods Inclusion criteria: Perinatally acquired HIV infection Aged <18 years Were receiving first-line NNRTI-based cART Had a documented history of viral suppression (two consecutive pVL <400 copies/ml at least 6 months apart) Exclusion criteria: Exposed to mono/dual therapy prior starting cART
Slide 7-

Definitions The frequency of pVL testing: Determined at site-level Based on a median rate of pVL measurement at each clinical site over the entire follow-up period in TApHOD ***Patients from sites with a median monitoring rate <0.75 test/patient/year over the entire follow-up period in TApHOD were excluded*** Annual monitoring A median rate of 0.75- 1.5 tests/patient/year Semi-annual monitoring A median rate >1.5 tests/patient/year
Slide 8-

Definitions Treatment failure (outcome of interest): 2 consecutive pVL >1000 copies/ml, or A change of antiretroviral drug class, or Death Loss to follow-up: Not having been seen in clinic for >12 months without documentation of transfer
Slide 9-

Statistical analysis Kaplan-Meier estimates and log-rank tests: Describe and compare the cumulative probability of detecting treatment failure by pVL monitoring frequency Baseline: The date of the 2nd pVL <400 copies/ml Censor: Last clinic visit Competing-risks regression models: Identify factors associated with treatment failure Loss to follow-up was considered a competing event A 2-tail P <0.05 was considered statistically significant
Slide 10-

Site-specific rates of pVL monitoring *Less than annual, <0.75 tests/patient/year; Annual, 0.75-1.5 tests/patient/year; Semi-annual, >1.5 tests/patient/year
Slide 11-

Participant characteristics Of 10 clinical sites, 1220 children were eligible 1042 children (85%) were from 6 sites which performed annual pVL monitoring 178 children (15%) were from 4 sites which performed semi-annual pVL monitoring
Slide 12-

*Characteristics were at baseline (date of the 2nd pVL <400 copies/ml), unless otherwise specified. †Data were presented as n (%) for categorical data and medians (interquartile range) for continuous data.
Slide 13-

*Characteristics were at baseline (date of the 2nd pVL <400 copies/ml), unless otherwise specified. †Data were presented as n (%) for categorical data and median (interquartile range) for continuous data.
Slide 14-

Incidence of treatment failure Median follow-up time was 4.6 (IQR 2.2 - 6.6) years 20 children (1.6%) were lost to follow-up, incidence rate of 0.4 (95%CI: 0.2-0.5) per 100 person-years of follow-up (PYFU) Treatment failure developed in 258 children (25%) with annual pVL monitoring, incidence rate of 5.4 (95% CI: 4.8-6.1) per 100 PYFU 40 children (23%) with semi-annual pVL monitoring, incidence rate of 4.3 (95% CI: 3.1-5.8) per 100 PYFU
Slide 15-

Kaplan-Meier estimates of cumulative probability of detecting treatment failure by pVL monitoring frequency
Slide 16-

Predictors of treatment failure among perinatally HIV-infected children on stable first-line NNRTI–based cART *Characteristics represent the conditions at baseline (date of the 2nd pVL <400 copies/ml). †Multivariable model adjusted by frequency of pVL measurement, age, orphan status, school attendance, HIV disclosure status, height-for-age z-score, pVL at cART initiation, the most severe WHO clinical stage, duration of cART, and current CD4 T-cell percentage.
Slide 17-

Characteristics of HIV-infected children with treatment failure *Data were presented as n(%) for categorical data and medians (interquartile range) for continuous data.
Slide 18-

Study limitations Selection bias towards sites that have higher level of resources to perform pVL measurement in their patients. Other treatment outcomes not evaluated – Development of opportunistic infections, hospitalizations, drug resistance
Slide 19-

Conclusions and discussion No significant difference between the rate of treatment failure detected by annual vs. semi-annual pVL monitoring in previously suppressed children. For suppressed children, annual pVL testing may be sufficient to monitor ART outcomes. Cost savings without jeopardizing patient safety Consistent with WHO 2016 recommendations Taking into consideration patient-level factors when determining monitoring frequency may help to balance clinical needs and program costs.
Slide 20-

Acknowledgements The patients, families, and site staff participating in the study Funders U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Cancer Institute, National Institute of Mental Health, National Institute on Drug Abuse as part of the International Epidemiology Databases to Evaluate AIDS (IeDEA; U01AI069907) AIDS Life Association, Austria

User Presentation
Related Presentations

Neuropsychological performance in African children with HIV enrolled in a multi-site anti-retroviral clinical trial

By: MarieAltmann
Views: 1759

HIV TESTING AT BIRTH – UPDATE FROM SOUTH AFRICA

By: MarieAltmann
Views: 2015

Children and COVID-19: State-Level Data Report

By: MarieAltmann
Views: 1762

Research Highlights: COVID-19 and Pediatric Populations

By: MarieAltmann
Views: 2155

Screening for Social Determinants of Health: Children's Hospitals Respond

By: MarieAltmann
Views: 1885

Graves Disease With Cardiovascular Complications

By: yoja22sari
Views: 1862

Intrauterine Growth Retardation-Restriction

By: FrankMarco
Views: 1905

APLASTIC ANEMIA

By: drdwayn
Views: 5317

Leukemia-Past Present and the Future

By: JenniferDwayne
Views: 1492

Sinais Vitais

By: valdymuniz
Views: 1749

MarieAltmann

About : I am a passionate Pediatrician with experience of working in world-renowned hospital systems as well as community-based clinics. I have skills like Advocacy, Team Building, Event Planning, and Public Speaking. A dedicated and worthy healthcare services professional with a MPH focused in International studies from Tulane School of Public Health and Tropical Medicine.
Occupation : Medical Professional
Specialty : MD
Country : United States of America
Website :

HEALTH A TO Z